Product Information
WIXELA 250-50 INHUB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.2451 per EA under NDC 00378932132. Its NADAC has been published 390 times since Apr 17, 2019.
FDA first approved this application on Jan 30, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250; 50 ug/1; ug/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378932132
Classification
Generic
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Generic (ANDA)
FDA Application
ANDA208891FDA Approved
1/30/2019
TE Code
AB
On Market Since
2/11/2019
Pharmacological Classes
Price Statistics
The NADAC for WIXELA 250-50 INHUB has been published 390 times since Apr 17, 2019, and over the history we have for it it has declined 67.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2451 per EA |
|---|---|
| All-time high | $3.7960 (May 15, 2019) |
| All-time low | $1.0972 (Apr 17, 2024) |
| 52-week high | $1.3646 |
| 52-week low | $1.2451 |
| Median price | $1.6339 |
| Average price | $1.8962 |
| Largest weekly change | -30.5% (Apr 17, 2024) |
| Weeks tracked | 390 |
| Tracking since | Apr 17, 2019 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone propionate and salmeterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of WIXELA 250-50 INHUB?
The current National Average Drug Acquisition Cost (NADAC) for WIXELA 250-50 INHUB, manufactured by Mylan Pharmaceuticals Inc., is $1.2451 per EA (NDC 00378932132), effective Sep 30, 2026.
How has the price of WIXELA 250-50 INHUB changed over time?
Over the history we have for it, the NADAC for WIXELA 250-50 INHUB has declined 67.2%. It has been tracked across 390 weekly CMS publications since Apr 17, 2019.
What are the highest and lowest recorded NADAC prices for WIXELA 250-50 INHUB?
Since Apr 17, 2019, the NADAC for WIXELA 250-50 INHUB has ranged from a low of $1.0972 (Apr 17, 2024) to a high of $3.7960 (May 15, 2019), with a median of $1.6339 per EA.
Are there cheaper alternatives to WIXELA 250-50 INHUB?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as WIXELA 250-50 INHUB in a comparable dosage form, but none are currently priced below it.
Who manufactures WIXELA 250-50 INHUB?
WIXELA 250-50 INHUB (NDC 00378932132) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.